Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GanShenAn is a Traditional Chinese Medicine (TCM) herbal formula developed by Shuguang Hospital, affiliated with the Shanghai University of Traditional Chinese Medicine, for the treatment of type 2 diabetes mellitus (T2DM). It is specifically formulated to address the TCM syndrome of liver-yin and kidney-yin deficiency, a common pattern in chronic metabolic disorders. The formula is designed to regulate blood glucose levels, improve insulin sensitivity, and alleviate clinical symptoms such as fatigue, thirst, and lower back soreness. Pharmacological research indicates that GanShenAn exerts its therapeutic effects by modulating glucose and lipid metabolism, potentially through the activation of the PI3K/Akt signaling pathway and the protection of pancreatic islet beta-cell function. It is typically administered as an oral granule or capsule and is utilized as a hospital preparation within the developer's clinical network.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GanShenAn.